423 related articles for article (PubMed ID: 8078529)
1. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
[TBL] [Abstract][Full Text] [Related]
2. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
3. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
4. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
5. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
6. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
7. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
Feagan BG; Rochon J; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Gillies R; Hopkins M
N Engl J Med; 1995 Feb; 332(5):292-7. PubMed ID: 7816064
[TBL] [Abstract][Full Text] [Related]
9. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
Feagan BG; Fedorak RN; Irvine EJ; Wild G; Sutherland L; Steinhart AH; Greenberg GR; Koval J; Wong CJ; Hopkins M; Hanauer SB; McDonald JW
N Engl J Med; 2000 Jun; 342(22):1627-32. PubMed ID: 10833208
[TBL] [Abstract][Full Text] [Related]
10. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
11. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-12 antibody for active Crohn's disease.
Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR; Feagan BG; Fedorak RN; Lashner BA; Panaccione R; Present DH; Spehlmann ME; Rutgeerts PJ; Tulassay Z; Volfova M; Wolf DC; Hernandez C; Bornstein J; Sandborn WJ;
Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
[TBL] [Abstract][Full Text] [Related]
15. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
[TBL] [Abstract][Full Text] [Related]
16. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
17. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
18. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
19. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
20. Sargramostim for active Crohn's disease.
Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
